ArticleScientific reports2018
Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Adenoviral-vectored neoantigen vaccine augments hyperexpanded CD8Journal for immunotherapy of cancer · 2024Article
- Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults.Wellcome open research · 2024Article
- HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV.JHEP reports : innovation in hepatology · 2023Article
- A five-antigen Esx-5a fusion delivered as a prime-boost regimen protects againstFrontiers in immunology · 2023Article
- Viral delivery of a peptide-based immunomodulator enhances T cell priming during vaccination.Frontiers in pharmacology · 2022Article
- Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.Journal for immunotherapy of cancer · 2021Article
- Cancer Associated Endogenous Retroviruses: Ideal Immune Targets for Adenovirus-Based Immunotherapy.International journal of molecular sciences · 2020Review
- MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.Science translational medicine · 2020Article
- Article
- Targeting Antigen to the Surface of EVs Improves theMolecular therapy. Methods & clinical development · 2020Article
- Use of an Outbred Rat Hepacivirus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus.Hepatology (Baltimore, Md.) · 2020Article
- Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria.Infection and immunity · 2020Article
- Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines.Frontiers in immunology · 2020Review
- Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses.Frontiers in immunology · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Despite promising progress in malaria vaccine development, an efficacious subunit vaccine against P. falciparum remains to be licensed and deployed. This study aimed to improve on the immunogenicity of the leading liver-stage vaccine candidate (ChAd63-MVA ME-TRAP), known to confer protection by eliciting high levels of antigen-specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.